DeepInfra | $107,000,000 | (May 5, 2026)
Kibu, Inc | $10,500,000 | (May 5, 2026)
Fun | $72,000,000 | (May 5, 2026)
ImmuneWalk Therapeutics
United States
- Pearl River, New York
- 08/05/2025
- Seed
- $7,000,000
ImmuneWalk Therapeutics is a private clinical-stage company focused on development of novel therapies for chronic inflammatory diseases. Our Monocyte Targeting Technology (MTT) is designed to selectively block the migration (`walking`) of monocytes from the blood stream into inflamed tissues. Our lead candidate, IW-601, is a proprietary monoclonal antibody that is engineered to specifically prevent monocytes from exiting the blood stream and traveling to inflammatory sites. IW-601 is designed to offer a novel and differentiated approach in the landscape of current anti-inflammatory agents.
With clear disease-modifying activity in models of Multiple Sclerosis, Rheumatoid Arthritis, Inflammatory Bowel Disease and Non- Alcoholic Steatohepatitis, in addition to proof-of-concept from patient’s cells, we are advancing IW-601 to a Ph1 clinical trial.
- Industry Biotechnology Research
- Website https://immunewalk.com/
- LinkedIn https://www.linkedin.com/company/immunewalk-therapeutics/
Panthalassa | $140,000,000 | (May 5, 2026)
Featherless AI | $20,000,000 | (May 5, 2026)
Healthfab | $2,100,000 | (May 5, 2026)
LakeFusion | $7,500,000 | (May 5, 2026)
Enzo Health | $20,000,000 | (May 5, 2026)
Barocal | $10,000,000 | (May 5, 2026)
Zapdos Labs | $500,000 | (May 5, 2026)
Blomma | $5,000,000 | (May 1, 2026)
Dreambase | $3,700,000 | (May 1, 2026)